Pulmonary Embolism (PE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Pulmonary Embolism (PE) Market Outlook

Thelansis’s “Pulmonary Embolism (PE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Embolism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pulmonary Embolism (PE) Overview

Pulmonary embolism (PE) is a systemic arterial systolic pressure below 90 mmHg that does not respond to pressor agents. PE is often called "the great masquerader" due to its ability to mimic the signs and symptoms of other diseases. The majority of clinically significant PEs originate from venous thromboembolisms (VTEs) that develop in the lower extremities or pelvic veins. In rarer cases, upper extremity thromboembolic events can result in PE. The development of VTE is associated with various conditions. Virchow's triad, consisting of hypercoagulability, venous stasis, and vessel wall injury, provides a model for understanding many risk factors. These factors can be either inherited or acquired. Major risk factors for thromboembolic events include recent immobilization, myocardial infarction (MI), cerebrovascular accident (CVA), surgery, and trauma. Failure to diagnose PE is a severe management error, as untreated patients have a mortality rate of 30%, whereas, with effective therapy, the mortality rate decreases to 8%. PE can be asymptomatic or present with sudden death. Common signs include tachypnea (54%) and tachycardia (24%). The most frequently reported symptoms are dyspnea, often occurring within seconds, either at rest or during exertion (73%), pleuritic pain (44%), calf or thigh pain (44%), calf or thigh swelling (41%), and cough (34%). Treatment options for PE include thrombolysis and anticoagulation using heparins and oral vitamin K antagonists. A minority of patients do not experience clot resolution and subsequently develop chronic thromboembolic disease.

• In the United States, the estimated incidence of PE is 65 cases per 100,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: